Race Oncology Ltd (RAC:ASX)


right-arrow Created with Sketch. 0.04 (1.24%)
MCAP $471.8M
Last trade 14.15pm 28/10/2021 20mins delayed

Latest Announcements

11.35am 28/10/2021 Price SensitivePSRACRace Oncology Ltd
27/10/2021RACRace Oncology Ltd
21/10/2021RACRace Oncology Ltd
21/10/2021RACRace Oncology Ltd
19/10/2021 Price SensitivePSRACRace Oncology Ltd
13/10/2021RACRace Oncology Ltd
06/10/2021 Price SensitivePSRACRace Oncology Ltd
05/10/2021RACRace Oncology Ltd

Company Overview

Race Oncology Limited (Race) is an Australia-based precision oncology company with a Phase 2/3 cancer drug, Bisantrene. Bisantrene is a small molecule inhibitor of the fat mass and obesity associated (FTO) protein. The Company is targeting the use of Bisantrene in melanoma and clear cell renal cell carcinoma (kidney cancer), both frequent FTO-driven cancers. Race also has clinical data for the use of Bisantrene in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers.

RAC in the news

Race Oncology (RAC) is granted its sixth US patent for its cancer…
Race Oncology (RAC) secures another US patent for its cancer drug ZantreneThis…
Race Oncology’s (RAC) Zantrene treatment has been proven to kill melanoma cancer…
The first patient in Race Oncology’s (RAC) Phase 1b/2 acute myeloid leukaemia…

Search Previous Announcements